CREATE Medicines (Biotechnology, Health and Wellness) — Funding, Investors & Signals 2026

CREATE Medicines

Founded 2019

Cambridge, United States 43 employees Series A Total: $219.00M Biotechnology, Health and Wellness +1

Myeloid Therapeutics is a biotechnology startup founded in 2019 and headquartered in the United States. The company has garnered significant attention and investment, with their most recent Series A investment totaling a substantial $73.00M and led by prominent investors such as 8VC, Arch Venture Partners, Hatteras Venture Partners, Alexandria Venture Investments, Moore Strategic Ventures, and Newpath Partners. Myeloid Therapeutics has focused its efforts on pioneering novel platform technologies that leverage the innate abilities of myeloid cells. Their expertise in advanced gene and cell therapies has culminated in the development of a clinical-stage, mRNA-immunotherapy pipeline aimed at delivering groundbreaking treatments for cancer. The company's dedication to translating knowledge into tangible solutions speaks volumes to their potential impact on the biotechnology landscape. With a clear mission to address unmet medical needs, Myeloid Therapeutics is poised to make significant strides in the field of oncology. Their innovative approach and strong investor support position them for success, offering a promising opportunity for venture capitalists looking to invest in groundbreaking advancements in cancer therapeutics.

Funding Stage	Amount	Investors	Date
Series A	••••••	6	18 May 2023
Grant	••••••	1	20 Feb 2023
Series A	••••••	3	06 Jan 2021

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

••••••

18 May 2023

Grant

••••••

20 Feb 2023

Series A

••••••

06 Jan 2021

FAQ About CREATE Medicines

CREATE Medicines is a clinical-stage biotech pioneering in vivo multi-immune programming. Its proprietary mRNA-LNP platform directly programs immune cells inside the body to deliver scalable, repeat-dose, off-the-shelf immunotherapies. With proven human validation and next-generation RNA technology,...

CREATE Medicines was founded in 2019.

CREATE Medicines is headquartered in Cambridge, United States.

CREATE Medicines operates in the following industries: Biotechnology, Health and Wellness, Life Sciences.

CREATE Medicines has approximately 43 employees.

CREATE Medicines has completed 3 funding rounds, raising a total of $219.00M. The latest funding stage is Series A.

Top alternatives and competitors to CREATE Medicines include Umoja Biopharma, GigaMune, Abintus Bio, Inc., Minutia , Genenta Science (Nasdaq: GNTA). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

CREATE Medicines and Umoja Biopharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

CREATE Medicines

General Information

Track CREATE Medicines

Discover More

About CREATE Medicines

Funding Rounds & Investors (3)

CREATE Medicines Alternatives & Competitors

FAQ About CREATE Medicines

Don't just browse. Track.